EverSource Wealth Advisors LLC Acquires 935 Shares of Thermo Fisher Scientific Inc. $TMO

EverSource Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 53.5% in the first quarter, Holdings Channel reports. The institutional investor owned 2,684 shares of the medical research company’s stock after acquiring an additional 935 shares during the period. EverSource Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,319,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of TMO. Howard Capital Management Inc. grew its holdings in Thermo Fisher Scientific by 0.5% during the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after purchasing an additional 16 shares during the period. Salomon & Ludwin LLC lifted its position in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after buying an additional 17 shares in the last quarter. Red Door Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock valued at $1,250,000 after acquiring an additional 18 shares during the period. Elwood & Goetz Wealth Advisory Group LLC raised its stake in Thermo Fisher Scientific by 1.8% during the 4th quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 1,031 shares of the medical research company’s stock worth $597,000 after acquiring an additional 18 shares during the period. Finally, Apella Capital LLC lifted its holdings in Thermo Fisher Scientific by 2.5% during the fourth quarter. Apella Capital LLC now owns 744 shares of the medical research company’s stock valued at $431,000 after purchasing an additional 18 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Evercore set a $570.00 price target on Thermo Fisher Scientific in a report on Monday, July 6th. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, Robert W. Baird cut their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $617.14.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO opened at $576.77 on Friday. The stock has a market capitalization of $214.34 billion, a PE ratio of 31.03, a P/E/G ratio of 2.34 and a beta of 0.87. The company’s fifty day moving average is $503.98 and its 200 day moving average is $511.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the company posted $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.